Polls

TREATMENT

Newport Healthcare’s Mental Health Treatment Efficacy Yields Industry-Leading Outcomes in 2020 | Surveys Polls And Research

NASHVILLE, Tenn., May 20, 2021 /PRNewswire/ — In a year defined by a global pandemic that included social isolation, collective trauma, and unprecedented stress, mental health emerged as a primary concern for families, with as many as three quarters of young people reporting increased mental health issues. Newport Healthcare, a national network of evidence-based healing centers for teens and young adults with primary mental health disorders, responded to the urgent demand for care and, in outcomes data compiled in collaboration with Drexel University’s Center for Family Intervention Science, is reporting statistically significant, industry-leading improvements of patient symptoms following treatment.

Over the course of 2020, 1,400 clients at multiple Newport Healthcare locations – including Newport Academy for teens and Newport Institute for young adults – were surveyed via validated assessment tools including the DSM-5-informed Patient Health Questionnaire (PHQ-9) that measures depression severity, the Generalized Anxiety Disorder Scale (GAD-7), and the

Read More Read More
TREATMENT

Oral Gepants Have Disrupted Acute Migraine Management and Look Next to Transform Preventive Treatment, According to Both Primary Care Physicians and Specialists | Surveys Polls And Research

EXTON, Pa., May 6, 2021 /PRNewswire/ — Both AbbVie’s (formerly Allergan, an AbbVie company) Ubrelvy and Biohaven’s Nurtec ODT are viewed by primary care physicians (PCPs) as strong entrants into the acute segment of the migraine market following their early 2020 launches. Interestingly, a new study from Spherix found similar physician-reported shares for both gepants [i.e., oral calcitonin gene-related peptide (CGRP) receptor antagonists], despite Ubrelvy’s earlier launch.  

In the inaugural semiannual report included in Spherix’s RealTime Dynamix™: Migraine – PCP Perspective (US) service, data collected from 96 PCPs found that, of the two gepants, direct comparison gives Nurtec ODT the advantage over Ubrelvy on most clinical metrics. Nurtec ODT best differentiates from Ubrelvy on duration of effect and convenience of patient administration among PCPs, consistent with its prevention label currently under FDA review and its unique orally dissolving tablet formulation, respectively.

Spherix has also been tracking the specialist-treated (i.e.,

Read More Read More
TREATMENT

Upcoming Oral, Small Molecule Agents Expected to Leapfrog Existing Biologic Treatment and Become Foundational Inflammatory Bowel Disease Therapies | Surveys Polls And Research

EXTON, Pa., March 24, 2021 /PRNewswire/ — Spherix recently surveyed 100 US gastroenterologists and followed up with seven qualitative interviews (including an industry key opinion leader) in order to assess the current pre-advanced systemic treatment algorithm for inflammatory bowel disease (IBD), along with the prospects for several oral, small molecule pipeline therapies. This new Special Topix™ service was created in response to the three oral, small molecule therapies currently in Phase 3 development for the treatment of IBD and the additional three therapies with Phase 2 clinical data.

Through ongoing research provided in Spherix’s core services offered in IBD, Spherix experts began to notice a possible paradigm shift in the way gastroenterologists are perceiving upcoming pipeline agents and how they intend on prescribing to biologic-naïve patients. The combination of qualitative and quantitative research included in the Special Topix™ service evaluates, in detail, the current treatment algorithm for pre-advanced systemic

Read More Read More